Controlled Release Delivery Conference 2018

SMi Group21 - 22 March, London, UK.
An industry-leading show, SMi have been running this conference for 15 years - a testament of how vital this particular focus is to the biotech and pharma sector. As physicians and scientists continue to find strategies to assist in simplifying treatment schedules for patients, a pharma focus continues to move towards innovative controlled release technologies to improve drug transport to target.

Moreover, with the global oral controlled release drug delivery technology market expected to expand at 7.2% CAGR between 2017-2027 (with an estimated revenue of US$50B by 2027), now is the time to get ahead of the game by exploring and understanding innovations in drug delivery, nanoparticles/nanomedicine & QbD, CNS drug delivery and therapeutic application.

Who will be speaking?

  • Howard Stevens, Emeritus Professor, University of Strathclyde (CHAIRMAN)
  • Joël Richard, Senior Vice President, Peptides Development, Ipsen (CHAIRMAN)
  • Mohamed Albed Alhnan, Senior Lecturer, University of Central Lancashire
  • Pavel Farkas, Senior Director - Biopharmaceutics/ Clinical Development, PLIVA
  • Barry Friend, Sr. Technical Manager, Colorcon
  • Sebastian Schwier, Project Director / Int. Technical Project Leader, ‎Grünenthal
  • Karsten Lindhardt, CSO, Head R&D, Egalet
  • Teofilo Vasconcelos, Formulation Manager, Bial
  • Guillaume Saint-Pierre, Chief Executive Officer and Cofounder, PeptiGelDesign

Highlights this March 2018

  • Understand the impact of the current EU Guideline on clinical evaluation of modified release drugs from a pharmaceutical perspective, with a talk from PLIVA
  • Discover new technologies and innovations for the development of Controlled Release drugs including Lipid-composite microparticles, Molecular Envelope Technology (MET) nanoparticles and Abuse-Deterrent Formulations
  • Focus on Successful Oral Technologies progressing in the clinic, with talks discussing lessons learned from clinical studies
  • Learn about the advances and challenges in Paediatric controlled release formulations, including taste-masking and oral formulation challenges
  • ...and more.

For further information and to register, please visit:
https://www.smi-online.co.uk/pharmaceuticals/uk/controlled-release

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

FDA grants priority review to Roche's cancer immun…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) a...

Kymriah® (tisagenlecleucel), first-in-class CAR-T …

Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication ...

Daily aspirin linked to higher risk in men

Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who are not exposed to daily aspirin, reports a new Northwestern Medicine study. W...

New leads on treating dementia and Alzheimer's

A new research study by scientists in Australia and the US provides an explanation for why clinical trials of drugs reducing proteins in the brain that were thought to ca...

Boehringer Ingelheim R&D pushes to transcend d…

Family-owned pharmaceutical company Boehringer Ingelheim has presented its latest pipeline updates at a Research & Development press conference entitled 'Transcending Dis...

Roche reports a strong start in 2018

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division in...

Novartis launches FocalView app, providing opportu…

Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease...

To treat pain, you need to treat the patient

People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy. Pain can be amplified, by depr...

A potential new weapon in the addiction battle: FD…

Cocaine and other drugs of abuse hijack the natural reward circuits in the brain. In part, that's why it's so hard to quit using these substances. Moreover, relapse rates...

Novo Nordisk participates in new research project …

Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find bet...

Chemical octopus catches sneaky cancer clues, trac…

Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until n...

Alcon Cares Project 100 commits to reducing catara…

Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to ...